Pavone R, Pacquement H, Pasquet M, et al. - Survival and late effects analysis of TGM95 study for childhood (≤18years) ovarian non-seminomatous germ cell tumors (NS-GCT) were conducted. No adjuvant treatment was provided to patients with localized tumors (FIGO-stage IA) (low-risk, LR). Patients with advanced-stage were administered 3-5 VBP (vinblastin-bleomycin-cisplatinum) in intermediate-risk group (IR: FIGO-stage IC-II-III and AFP < 15,000ng/ml) or 4-6 VIP (etoposide-ifosfamide-cisplatinum) in high-risk group (HiR: metastatic or AFP ≥ 15,000ng/ml). A total of 77 patients were included (median age = 12years). After a median follow-up of 13.4years, there was an occurrence of 12 events (8 relapses) and 6 deaths (2 GCT-related, 2 due to acute myeloid leukemia and 2 non-cancer related). Overall an excellent prognosis was recorded for childhood ovarian NS-GCTs with few late effects. Observations suggest a possible value of the low-intensive etoposide-free VBP regimen as an alternative in children with IR disease especially in cases of tumor rupture. Regular monitoring of the remaining ovary appears necessary given the risk of contralateral mature teratoma.